Serological screening for cytomegalovirus during pregnancy: A systematic review of clinical practice guidelines and consensus statements

Abstract

AbstractBackgroundCongenital cytomegalovirus (cCMV) is the most common congenital infection worldwide. cCMV can lead to severe long‐term sequelae, including neurological impairment and developmental delay. We performed a systematic review of clinical practice guidelines containing recommendations concerning serological screening for CMV during pregnancy.MethodWe performed a search of MEDLINE, Turning Research into Practice (TRIP) database and the grey literature for clinical practice guidelines or consensus statements published in the English language from Jan 2010 to June 2022. The quality of the included guidelines was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. Textual synthesis was used to summarise and compare the recommendations on CMV serological screening in pregnancy.ResultsEleven guidelines and two consensus statements were included. None recommended universal serological screening for CMV in pregnant women; five recommended screening for high‐risk women (those with frequent contact with young children). The overall quality of the guidelines varied; most were medium or low.ConclusionsAlthough clinical practice guidelines do not actively recommend routine serological screening in pregnancy, most did not meet standard processes for development and predated the emerging data on valaciclovir as a potential intervention. Existing recommendations are underpinned by limited, low‐level evidence, exposing the lack of robust data in this area of practice. Further high‐level evidence and methodologically robust guidelines are needed to guide clinical practice in this rapidly changing field.